Producer
Dr. Reddy's Laboratories
Major Indian pharmaceutical company (NYSE: RDY); one of India's largest generic drug manufacturers. Major tretinoin API producer; also produces wide range of generic APIs and formulations for US, EU, and global markets. Second-largest Indian pharma company by revenue. API manufacturing in Hyderabad, Vizag (Visakhapatnam), and other sites.
1
Inputs supplied
1
Goods downstream
1
Facilities
0
Stories
What they make
1 input Dr. Reddy's Laboratories supplies
Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.
Where it shows up
Goods downstream
Essential goods that depend on something Dr. Reddy's Laboratories makes — pick one to see the full supply chain.
What else they do
Business segments
The company's full revenue map — where this supply-chain role fits within their broader business.
Global Generics (US & Europe)
45%Pharmaceutical Services & Active Ingredients (PSAI)
28%Emerging Markets & India Business
18%Biosimilars & Proprietary Products
9%
Intelligence
What's known
Sourced claims about this company's role in supply chains — chokepoints, concentration, incidents, dual-use connections.
Origin2022
Dr. Reddy's Laboratories, founded in 1984 by K. Anji Reddy with personal savings of 25 lakh rupees (approximately $30,000 at the time) in Hyderabad, was the company that brought Indian pharmaceutical companies into the US generic drug market through aggressive use of Paragraph IV patent challenges — a legal mechanism in the Hatch-Waxman Act (1984) that allows generic manufacturers to challenge branded drug patents by claiming invalidity or non-infringement. Dr. Reddy's was an early and systematic user of Paragraph IV filings, becoming the first generic company to receive 180-day exclusivity in the US for omeprazole (Prilosec) in 2002, entering with a price roughly 70% below the branded drug. This strategy — essentially systematically suing branded pharmaceutical patent holders — reshaped US drug pricing and became the playbook adopted by Teva, Mylan, and dozens of other generic companies. K. Anji Reddy's background was in the Indian Drugs and Pharmaceuticals Limited (IDPL), a public sector company, before he founded Dr. Reddy's — making it a story of public sector scientific training used to build a private generics empire that would eventually earn $3 billion+ in annual revenue and save US consumers and insurance systems tens of billions in drug costs.
Dr. Reddy's Laboratories Ltd. ↗